Annotation Detail
Information
- Associated Genes
- FGFR1
- Associated Variants
-
FGFR1 AMPLIFICATION
(
ENST00000425967.8 )
FGFR1 AMPLIFICATION ( ENST00000425967.8 ) - Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- Clinical trial studied the efficacy of Dovitinib on 26 patients with FGFR1 amplifications. Objective response for the cohort was 11.5%, disease control rate was 50%. 11.5% of patients exhibited partial response, 38.5% exhibited stable disease. Median PFS was 2.9 months, median OS was 5 months, this trend was worse with increases in FGFR1 amplification above average.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/3027
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1885
- Variant URL
- https://civic.genome.wustl.edu/links/variants/267
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Dovitinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 27315356
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dovitinib | Sensitivity | true |